登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002173 证券简称：创新医疗 公告编号：2025-054 创新医疗管理股份有限公司 关于诉讼事项的进展公告（二） 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，创新医疗管理股份有限公司（以下简称"公司"）收到了上海金融法院《传票》等。上海金融法院 定于2025年12月10日，开庭审理韩猛与公司及公司时任董事有关损害股东利益责任纠纷一案。相关情况 如下： 二、上述案件对公司本期利润或期后利润的可能影响 上述案件尚未开庭审理。公司将持续关注后续进展情况，并按照有关规定及时履行信息披露义务。敬请 广大投资者注意投资风险。 三、公司是否有其他尚未披露的诉讼仲裁事项 截止本公告日，公司及控股子公司不存在应披露而尚未披露的其他重大诉讼、仲裁事项。 四、备查文件 上海金融法院《传票》等相关文件。 一、上述案件相关情况 （一）一审判决情况 2025年9月，公司收到上海市浦东新区人民法院《民事判决书》（（2025）沪0115民初26824号）。上海 市浦东新区人民法院对韩猛以公司未办理相关股份的解除限售手续 ...

Core Points - Innovation Medical (002173) closed at 21.24 yuan on November 27, 2025, down 1.03% from the previous trading day, with a total market capitalization of 9.373 billion yuan [1] - The stock opened at 21.23 yuan, reached a high of 21.6 yuan, and a low of 21.11 yuan, with a trading volume of 388 million yuan and a turnover rate of 4.36% [1] - The company announced it received a summons from the Shanghai Financial Court regarding a shareholder interest damage liability dispute involving Han Meng and the company's former directors, with a hearing scheduled for December 10, 2025 [1] - The Shanghai Pudong New District People's Court previously issued a first-instance judgment on the case, which both the company and Han Meng appealed [1] - The company stated it will continue to monitor the case's progress and fulfill its information disclosure obligations, with no other significant litigation or arbitration matters pending as of the announcement date [1]

（文章来源：证券日报） 证券日报网讯 11月28日，创新医疗发布公告称，近日，公司收到了上海金融法院《传票》等。上海金 融法院定于2025年12月10日，开庭审理韩猛与公司及公司时任董事有关损害股东利益责任纠纷一案。 ...

此外，公告还披露，截至本公告日，公司及控股子公司不存在应披露而尚未披露的其他重大诉讼、仲裁 事项。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 登录新浪财经APP 搜索【信披】查看更多考评等级 创新医疗管理股份有限公司（证券代码：002173，证券简称：创新医疗）11月28日发布诉讼事项进展公 告称，公司近日收到上海金融法院《传票》，该院定于2025年12月10日开庭审理韩猛与公司及公司时任 董事之间的损害股东利益责任纠纷上诉一案。该案源于双方对此前一审判决均不服，已分别向上海金融 法院提起上诉。 公告显示，该案一审由上海市浦东新区人民法院审理。2025年9月，公司收到该院（2025）沪0115民初 26824号《民事判 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-054 创新医疗管理股份有限公司 关于诉讼事项的进展公告（二） 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，创新医疗管理股份有限公司（以下简称"公司"）收到了上海金融法 院《传票》等。上海金融法院定于 2025 年 12 月 10 日，开庭审理韩猛与公司及 公司时任董事有关损害股东利益责任纠纷一案。相关情况如下： 本案中，公司和韩猛均不服上述一审判决，向上海金融法院提起上诉。上海 金融法院定于 2025 年 12 月 10 日开庭审理本案。 二、上述案件对公司本期利润或期后利润的可能影响 上述案件尚未开庭审理。公司将持续关注后续进展情况，并按照有关规定及 时履行信息披露义务。敬请广大投资者注意投资风险。 1 / 2 三、公司是否有其他尚未披露的诉讼仲裁事项 截止本公告日，公司及控股子公司不存在应披露而尚未披露的其他重大诉讼、 仲裁事项。 一、上述案件相关情况 （一）一审判决情况 2025年9月，公司收到上海市浦东新区人民法院《民事判决书》（（2025） 沪0115民初26824号）。上海 ...

Core Viewpoint - As of November 24, 2025, Innovation Medical (002173) closed at 21.12 yuan, marking a 2.52% increase, with a trading volume of 210,800 hands and a transaction value of 441 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, the company's main revenue was 597 million yuan, a year-on-year decrease of 2.11% [3] - The net profit attributable to shareholders was 4.7244 million yuan, a year-on-year increase of 116.97% [3] - The third quarter of 2025 saw a single-quarter main revenue of 196 million yuan, down 3.16% year-on-year, while the single-quarter net profit attributable to shareholders was 16.0857 million yuan, up 236.15% year-on-year [3] - The company reported a debt ratio of 17.84% and investment income of 29.5055 million yuan [3] Group 2: Market Activity - On November 24, 2025, the net inflow of main funds was 42.1095 million yuan, accounting for 9.56% of the total transaction value [1][2] - Over the past five days, the stock experienced fluctuations, with a notable net outflow of main funds on November 21 and November 20, amounting to 43.7524 million yuan and 64.4199 million yuan respectively [2] - The stock's performance in terms of trading volume and turnover indicates active market participation, with a turnover rate of 5.06% on November 24 [1] Group 3: Industry Comparison - Innovation Medical's total market value is 9.32 billion yuan, significantly lower than the industry average of 18.81 billion yuan, ranking 16th out of 42 in the medical services sector [3] - The company's price-to-earnings ratio (P/E) stands at 1479.53, compared to the industry average of 359.81, indicating a relatively high valuation [3] - The gross margin of Innovation Medical is 10.08%, which is considerably lower than the industry average of 35.56%, ranking 40th out of 42 [3]

Core Insights - Innovation Medical (002173) reported a closing price of 21.72 yuan on November 19, 2025, with a slight increase of 0.18% and a trading volume of 211,800 hands, resulting in a total transaction value of 455 million yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a main operating revenue of 597 million yuan, a year-on-year decrease of 2.11% [3] - The net profit attributable to shareholders was 4.72 million yuan, showing a significant year-on-year increase of 116.97% [3] - The third quarter of 2025 saw a single-quarter main operating revenue of 196 million yuan, down 3.16% year-on-year, while the single-quarter net profit attributable to shareholders was 16.09 million yuan, up 236.15% year-on-year [3] - The company reported a debt ratio of 17.84% and investment income of 29.51 million yuan, with financial expenses amounting to 605,500 yuan [3] Market Position - The total market capitalization of Innovation Medical is 9.585 billion yuan, ranking 15th in the medical services industry, which has an average market cap of 19.169 billion yuan [3] - The company's net assets stand at 1.79 billion yuan, with an industry average of 5.977 billion yuan, placing it 27th in the industry [3] - The price-to-earnings ratio (P/E) is 1521.56, significantly higher than the industry average of 376.65, ranking 33rd [3] - The gross margin is reported at 10.08%, compared to the industry average of 35.56%, ranking 40th [3] Capital Flow Analysis - On November 19, 2025, the main funds experienced a net outflow of 36.79 million yuan, accounting for 8.08% of the total transaction value, while retail investors saw a net inflow of 52.29 million yuan, representing 11.48% of the total transaction value [1][2] - Over the past five days, the stock has seen fluctuating capital flows, with notable net outflows from both main and speculative funds on several days [2]

Market Overview - The medical services sector experienced a decline of 1.09% on November 19, with Jiuzhou Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Individual Stock Performance - Jiuzhou Pharmaceutical (603456) saw a significant drop of 6.24%, closing at 20.12, with a trading volume of 446,900 shares and a turnover of 915 million [2] - Other notable declines included Zhaoyan New Drug (603127) down 5.08% and ST Zhongzhu (600568) down 5.04% [2] - In contrast, some stocks like WuXi AppTec (603259) and Haoyuan Pharmaceutical (688131) showed slight increases of 0.95% and 0.34%, respectively [1] Capital Flow Analysis - The medical services sector experienced a net outflow of 885 million from institutional investors, while retail investors saw a net inflow of 877 million [2][3] - The data indicates that institutional investors are pulling back, while retail investors are actively buying into the sector [3] Stock-Specific Capital Flow - WuXi AppTec (603259) had a net inflow of 66.82 million from institutional investors, while it faced a net outflow of 15.56 million from retail investors [3] - Other stocks like Yinuo Pharmaceutical (688710) and Sunshine Nuohua (688621) also showed mixed capital flows, with varying degrees of institutional and retail investor activity [3]

Core Insights - Innovation Medical's stock price decreased by 2.03% on November 19, trading at 21.24 CNY per share with a total market capitalization of 9.373 billion CNY [1] - The company has seen a significant stock price increase of 166.83% year-to-date, but has experienced declines of 9.50% over the last five trading days, 9.69% over the last twenty days, and 14.49% over the last sixty days [1] - The company has been active in the stock market, appearing on the "Dragon and Tiger List" 19 times this year, with the most recent appearance on October 20, where it recorded a net buy of 242 million CNY [1] Financial Performance - For the period from January to September 2025, Innovation Medical reported a revenue of 597 million CNY, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders was 4.7244 million CNY, reflecting a year-on-year increase of 116.97% [2] - The company has a primary business focus on medical services, which accounts for 99.73% of its revenue, with other income contributing only 0.27% [1] Shareholder Information - As of September 30, the number of shareholders for Innovation Medical reached 130,200, an increase of 58.75% from the previous period, while the average number of circulating shares per shareholder decreased by 37.01% to 3,196 shares [2] Dividend Information - Since its A-share listing, Innovation Medical has distributed a total of 55.8729 million CNY in dividends, with no dividends paid in the last three years [3]

Core Insights - The conference on innovative medical health intelligent service supply and demand matching was held in Zhenjiang, marking a significant step towards high-quality development driven by data elements in the healthcare sector [1] - The event gathered over 70 participants, including 10 hospitals, 7 medical technology companies, and 3 insurance companies, indicating strong collaboration among various stakeholders in the healthcare ecosystem [1] Group 1 - Zhenjiang Mobile's Vice General Manager Zhang Weiping presented the company's technological layout and innovative achievements in data element operation services [1] - The Zhenjiang Data Group shared its experiences in public data authorized operation paths, highlighting practical applications in the healthcare sector [1] - Five representatives from data service companies demonstrated innovative smart service products, including AI-assisted diagnosis and intelligent risk control for medical insurance [1] Group 2 - Representatives from hospitals, medical enterprises, and insurance companies engaged in on-site discussions regarding the demand for intelligent services, showcasing the collaborative spirit of the industry [1] - Zhenjiang's Medical Insurance Center Deputy Director Chen Kai outlined the city's achievements in empowering healthcare intelligent services through data [1] - Zhenjiang's Health Information Center Director Zhu Yuelan discussed data governance and data security protection, emphasizing the importance of these aspects in healthcare data management [1] Group 3 - Zhenjiang Data Bureau Deputy Director Xu Dan proposed four requirements for the implementation of application scenarios: acting as a bridge, aggregating strength, exploring paths, and optimizing the ecosystem [1] - The conference served as a new exploration path and communication platform for government-enterprise cooperation and data industry development in the healthcare sector [1]